Aprea Therapeutics Reports Q4 and Full Year 2025 Financials: Early Clinical Successes, Strategic Hires, and Funding Bolster Outlook

Key Highlights

• Early clinical proof-of-concept for WEE1 inhibitor APR-1051: Two patients with PPP2R1A-mutated endometrial cancer showed unconfirmed partial responses at the first scan, indicating promising anti-tumor activity.
• Strengthened clinical leadership: Appointment of Dr. Eugene (Gene) Kennedy as Chief Medical Advisor to support the next phase of clinical development.
• Solid cash position: Cash and cash equivalents were \$14.6 million as of December 31, 2025, supplemented by \$8.7 million raised in private placements, expected to fund operations into Q1 2027.
• Pipeline update: Dose escalation ongoing for APR-1051; ATRN-119 ATR inhibitor pivoting toward combination strategies after RP2D determination.
• Operating expenses and net loss: Lower R&D expenses led to reduced quarterly losses; net loss per share improved year-over-year.

Clinical and Corporate Developments

ACESOT-1051: Promising Early Efficacy for WEE1 Inhibitor in Genomically Defined Cancers

Aprea’s lead candidate, APR-1051, a potent and selective oral WEE1 inhibitor, continues to show encouraging results in the ongoing Phase 1 ACESOT-1051 trial targeting biomarker-defined cancers, particularly those with PPP2R1A, FBXW7 mutations, HPV+ status, and Cyclin E overexpression—all populations with significant unmet needs and poor prognosis.

• January 29, 2026: First unconfirmed partial response (uPR) observed in a PPP2R1A-mutated uterine serous carcinoma patient treated at 150 mg. Achieved a 50% reduction in target lesion size at 8 weeks, and CA-125 tumor marker dropped from 732 to 70 U/mL, indicating robust anti-tumor activity.
• February 18, 2026: Second uPR in another PPP2R1A-mutated endometrial cancer patient at the 220 mg dose level. Also achieved a 50% tumor reduction and a CA-125 decrease from 362 to 47 U/mL.
• Five additional patients achieved stable disease, including HPV+ head and neck squamous cell carcinoma (HNSCC), colorectal, and endometrial cancers with relevant genomic alterations.
• Safety: APR-1051 has been well tolerated; most common adverse events were Grade 1 or 2 nausea and fatigue.
• Dose escalation ongoing: Patients are currently being treated at 220 mg (Dose Level 8), with plans to enrich for endometrial, colorectal, and HPV+ tumors. A further update is expected in Q2 2026.

ABOYA-119: ATR Inhibitor ATRN-119 Shifts Toward Combination Approaches

• ATRN-119: Aprea determined the recommended Phase 2 dose (RP2D) at 1,100 mg once daily. Following this, enrollment in monotherapy arms was paused and trial site activities are winding down as the focus shifts to exploring ATRN-119 in combination with radiation and other therapies.
• Potential combinations: Discussions underway with top academic institutions for studies in HPV+ head and neck cancer, and investigator-led studies with immuno-oncology therapies and antibody-drug conjugates are also being considered.

Corporate Updates and Capital Raises

• Private placements: Two successful rounds in December 2025 and January 2026 raised gross proceeds of approximately \$3.1 million and \$5.6 million, respectively.
• Leadership: Dr. Eugene Kennedy, a seasoned oncology executive, joined as Chief Medical Advisor in February 2026, bringing over 20 years of experience in clinical development and regulatory affairs.

Financial Overview

• Cash and cash equivalents: \$14.6 million as of December 31, 2025 (down from \$22.8 million in 2024), with additional proceeds from January 2026 private placement supporting operations into Q1 2027.
• Q4 2025 operating loss: \$2.6 million (improved from \$3.2 million Q4 2024).
• Q4 R&D expense: \$1.0 million, down from \$2.4 million in Q4 2024, due to lower trial costs and reduced personnel expenses.
• Q4 G&A expense: \$1.6 million, up from \$1.1 million in Q4 2024, primarily due to executive incentive compensation.
• Q4 net loss: \$2.5 million (\$0.32 per share) on 7.7 million shares, compared to \$2.9 million (\$0.49 per share) on 6.0 million shares in Q4 2024.
• Full year 2025 operating loss: \$13.2 million (improved from \$14.3 million in 2024). Net loss for 2025 was \$12.6 million (\$1.93 per share) on 6.5 million shares, compared to \$13.0 million (\$2.35 per share) on 5.5 million shares in 2024.
• Full year R&D expense: \$7.0 million (down from \$9.4 million in 2024), reflecting paused trials and decreased consulting and personnel costs.
• Full year G&A expense: \$6.5 million (flat year-over-year).
• Grant revenue: \$0.3 million in 2025 (down from \$1.5 million in 2024).

Shareholder-Relevant and Potentially Price Sensitive Items

• Clinical proof-of-concept for APR-1051: Partial responses in biomarker-defined patients could be a significant catalyst if confirmed and extended in future updates.
• Cash runway into 2027: The company remains well funded following recent capital raises, mitigating near-term dilution risk.
• Strategic pipeline pivot: The focus on combination approaches for ATRN-119 and strong early signals from APR-1051 position Aprea for potential value inflection points in 2026.
• Leadership strengthening: Addition of Dr. Kennedy may enhance execution in clinical development and regulatory strategy.

Outlook

Aprea Therapeutics enters 2026 with substantial momentum, a strengthened clinical team, and a solid cash position. Key upcoming catalysts include additional efficacy data from the ACESOT-1051 trial in Q2 2026 and further progress in combination trials for ATRN-119. While the company reduced operating losses and maintained G&A costs, future share price may be sensitive to clinical updates, capital requirements, and the company’s ability to advance its lead programs through pivotal study stages.

About Aprea Therapeutics

Aprea is a clinical-stage precision oncology company developing targeted therapies for biomarker-defined cancers. Its pipeline includes APR-1051 (WEE1 inhibitor) and ATRN-119 (ATR inhibitor), with a focus on treating ovarian, endometrial, colorectal, and head and neck cancers. For more, visit www.aprea.com.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

View Aprea Therapeutics, Inc. Historical chart here